---
title: "恒大人壽三任董事長等 20 名高管被罰：涉保險資金運用、利益輸送等"
description: "國家金融監督管理總局披露的罰單顯示，恒大人壽保險有限公司 20 名相關責任人員被罰。就處罰案由來看，罰單顯示，恒大人壽相關責任人員存在保險資金運用嚴重不合規、向關聯方輸送利益，投後管理不合規，報送的報告報表存在虛假記載等違法違規行為。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/257088359.md"
published_at: "2025-09-12T11:07:01.000Z"
---

# 恒大人壽三任董事長等 20 名高管被罰：涉保險資金運用、利益輸送等

> 國家金融監督管理總局披露的罰單顯示，恒大人壽保險有限公司 20 名相關責任人員被罰。就處罰案由來看，罰單顯示，恒大人壽相關責任人員存在保險資金運用嚴重不合規、向關聯方輸送利益，投後管理不合規，報送的報告報表存在虛假記載等違法違規行為。

國家金融監督管理總局披露的罰單顯示，恒大人壽保險有限公司 20 名相關責任人員被罰。就處罰案由來看，罰單顯示，恒大人壽相關責任人員存在保險資金運用嚴重不合規、向關聯方輸送利益，投後管理不合規，報送的報告報表存在虛假記載等違法違規行為。

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/zh-HK/news/276024005.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/zh-HK/news/275851575.md) |
| Aequs Entered Into MoU With Government Of Tamil Nadu For Setting Up Manufacturing Unit | Aequs Ltd :AEQUS LTD - ENTERED INTO NON- BINDING MEMORANDUM OF UNDERSTANDING WITH GUIDANCEAEQUS- ENTERS MOU WITH GOVERNM | [Link](https://longbridge.com/zh-HK/news/276049940.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/zh-HK/news/276016059.md) |
| Canada's Manulife Q4 core earnings rise 5% | Canada's Manulife reported a 5% year-over-year increase in Q4 core earnings, with adjusted EPS surpassing analyst expect | [Link](https://longbridge.com/zh-HK/news/275667029.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。